成纤维细胞激活蛋白抑制剂PET揭示梗死瘢痕以外的活跃成纤维细胞驱动重构
本研究为前瞻性研究,纳入31例心肌梗死后患者(早期≤1个月10例,晚期>1个月21例)和10例对照,采用[68Ga]Ga-FAPI-46 PET/CT、[18F]FDG PET/CT及[99mTc]Tc-MIBI SPECT多示踪剂分子成像。结果显示87%心梗患者存在心肌FAPI摄取,且高于对照;FAPI摄取可延伸至代谢保留心肌,提示空间异质性成纤维细胞相关重构。
要点
- 心梗后87%患者存在心肌FAPI摄取,提示活跃成纤维细胞介导的重构。
- FAPI摄取可见于代谢不活跃梗死区及部分代谢保留心肌,呈空间异质性。
- 早晚期心梗后患者FAPI定量参数无显著差异。
核心结论
- [68Ga]Ga-FAPI-46 PET/CT可无创显示心梗后活跃的成纤维细胞相关心肌重构。
研究设计与样本
- 前瞻性研究纳入31例心梗后患者(早期≤1个月10例,晚期>1个月21例)和10例对照。
- 所有受试者接受[68Ga]Ga-FAPI-46 PET/CT、[18F]FDG PET/CT和[99mTc]Tc-MIBI SPECT多示踪剂成像。
主要发现
- 87%心梗患者存在心肌FAPI摄取,SUVmax 4.21 vs 2.64(P=0.01),SUVmean 2.46 vs 1.35(P=0.001)。
- 患者层面两种表型:修复型局限于代谢不活跃梗死区(48%),混合型累及梗死区和FDG保留心肌(52%)。
- 无患者表现为单纯FDG保留区FAPI阳性模式。
- 早晚期心梗后患者FAPI定量参数无显著差异。
- 以TLF中位数分层,较高FAPI负荷更常与混合纤维化模式相关。
关键数值与推荐
- FAPI定量参数包括SUVmax、SUVmean、成纤维细胞激活体积(FAV)和总病灶FAPI(TLF)。
- 按FAPI摄取与FDG代谢空间关系区分梗死相关和混合表型。
临床怎么用
- 多示踪剂分子成像可互补评估心梗后心肌重构的生物学特征。
- FAPI PET/CT有助于识别梗死瘢痕以外的活跃成纤维细胞介导重构。
局限性
- FDG保留心肌内FAPI摄取的临床意义尚需进一步研究。
- 样本量较小(31例患者和10例对照),结论需更大队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Post-myocardial infarction (MI) remodeling is driven by dynamic interactions between inflammatory and fibrotic processes. Conventional imaging techniques primarily detect established scar but fail to capture active fibroblast-mediated remodeling. OBJECTIVES: The aim of the present study was to determine whether [68Ga]Ga-FAPI-46 PET/CT (gallium-68 fibroblast activation protein inhibitor-46 positron emission tomography/computed tomography) can identify biologically active myocardial remodeling beyond established infarct scar using a multi-radiotracer molecular imaging approach in patients with early post-MI (≤1 month after MI) and late post-MI (greater than 1 month after MI). METHODS: In this prospective study, 31 patients with early post-MI (≤1 month after MI) (N = 10) or late post-MI (greater than 1 month after MI) (N = 21) and 10 control subjects underwent [68Ga]Ga-FAPI-46 PET/CT, 18F-fluorodeoxyglucose ([18F]FDG PET/CT), and myocardial perfusion imaging (MPI) using [99mTc]Tc-MIBI SPECT [technetium-99m methoxyisobutylisonitrile single-photon emission computed tomography combined with computed tomography]. FAPI uptake was quantified using maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), fibroblast activation volume (FAV), and total lesion FAPI (TLF). FAPI uptake patterns were characterized, according to their spatial relationship with FDG metabolism, distinguishing infarct-associated and mixed phenotypes. RESULTS: Myocardial FAPI uptake was observed in 87% of patients with MI and was significantly higher than in controls (SUVmax: 4.21 vs 2.64, P = 0.01; SUVmean: 2.46 vs 1.35, P = 0.001). In our cohort, 2 patient-level phenotypes were observed: A reparative pattern restricted to metabolically inactive infarct regions (48%) and a mixed pattern showing FAPI uptake in both infarct regions and FDG-preserved myocardium (52%). No patient exhibited a purely FDG-preserved FAPI-positive pattern. No significant differences in quantitative FAPI parameters were observed between early- and late post-MI. Notably, in a subset of patients, myocardial FAPI uptake extended beyond metabolically inactive infarct regions into adjacent FDG-preserved myocardium, suggesting spatially heterogeneous fibroblast-associated remodeling. Stratification based on median TLF demonstrated that higher FAPI burden was more frequently associated with mixed fibrosis patterns. Multi-radiotracer imaging enabled identification of hibernating myocardium in a subset of patients. CONCLUSIONS: [68Ga]Ga-FAPI-46 PET/CT enables noninvasive visualization of active fibroblast-associated myocardial remodeling following MI. Integrated assessment with [18F]FDG PET demonstrated spatially heterogeneous FAPI uptake involving metabolically inactive infarct regions and, in a subset of patients, adjacent FDG-preserved myocardium. The complementary information provided by these radiotracers may improve biological characterization of post-infarction myocardial remodeling, although the significance of FAPI uptake within FDG-preserved myocardium requires further investigation.
引用
- Pourbehi MR, Juweid ME, Jafari E, et al. Fibroblast activation protein inhibitor positron emission tomography reveals active fibroblast-driven remodeling beyond infarct scar. J Nucl Cardiol. 2026. PMID: 42822823. doi:10.1016/j.nuclcard.2026.102979
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。